551 Health claim verifications avg. score 5.1/10 219 rated (mostly) true 266 rated (mostly) false
“A deficiency of estrogen (female sex hormones) can be a cause of underweight in people of any sex.”
The evidence does not support estrogen deficiency as a cause of underweight. In the stronger medical literature, low estrogen is more often linked to increased fat mass and weight gain, while underweight and calorie deficiency commonly cause low estrogen by suppressing reproductive hormone function. The claim reverses the usual direction of causation and overgeneralizes across sexes.
“Women with excessive muscle mass have reduced estrogen levels.”
The evidence does not support a general rule that muscular women have reduced estrogen levels. Most higher-quality research indicates estrogen helps preserve and build muscle in women, while low estrogen is more often linked to muscle loss or menopause-related decline. Cases where very lean or elite female athletes have low estrogen are usually explained by low energy availability, menstrual dysfunction, or other confounders rather than muscle mass itself.
“Excessive muscle mass in men causes estrogen deficiency.”
The evidence does not support the idea that excessive muscle mass in men causes estrogen deficiency. In men, low estrogen is usually linked to low testosterone, impaired aromatization, certain drugs, or endocrine disease—not to having a lot of muscle. Several credible sources point in the opposite direction or find no such causal relationship.
“In men, having low muscle mass causes estrogen levels to become abnormally high.”
The evidence does not support low muscle mass as a cause of abnormally high estrogen in men. Higher estradiol is more consistently associated with increased fat mass and aromatization, while studies often find weak, inconsistent, or no independent link between estradiol and muscle mass. The claim confuses low muscle with high body fat and overstates both causation and hormone abnormality.
“A cure for multiple sclerosis has been discovered.”
Current evidence does not support the statement that a cure for multiple sclerosis has been discovered. Authoritative medical sources explicitly say there is no cure for MS, while newer therapies only reduce relapses, slow progression, or show early repair potential. Promising trial results are not the same as a proven cure.
“South Korea has an approved medical treatment that regenerates knee cartilage in humans.”
South Korea does have an approved human treatment for knee cartilage defects that is described in regulatory, clinical, and independent sources as a regenerative cell therapy. The strongest evidence is MFDS approval of CARTISTEM and supporting clinical literature. The main caveat is that approval is for specific knee cartilage defects, not all forms of knee cartilage loss, and regeneration is not guaranteed in every patient.
“Excessive sugar intake lowers estrogen levels in women.”
The evidence does not support the claim that excessive sugar lowers estrogen levels in women. The strongest human studies cited point the other way, linking higher sugar intake with higher estradiol or lower SHBG, which can increase bioavailable estrogen. Animal and cell studies describe altered hormone regulation or estrogen action, but they do not establish that sugar lowers circulating estrogen in women.
“A person's hair length is associated with their personality traits.”
The evidence does not support a real association between hair length and a person’s underlying personality traits. Most studies in this area show that hair length changes how others perceive or stereotype someone, not who that person actually is. The best direct evidence cited found no significant personality differences by hair length, so the claim overstates what the research shows.
“Women with excessive body fat have elevated androgen levels.”
Excess adiposity in women is generally associated with a more androgenic hormonal profile, especially higher free or bioavailable testosterone. Multiple clinical and mechanistic studies support this pattern. The wording is broader than the evidence, though: not every specific androgen is elevated in every group, and some of the apparent increase reflects lower SHBG rather than uniformly higher total androgen levels.
“Obesity in men causes androgen deficiency.”
Obesity does appear to causally lower testosterone in men, and severe obesity can lead to genuine obesity-related hypogonadism. But the claim is too broad as stated: many obese men have lower total testosterone without true clinical androgen deficiency, because free testosterone may remain normal and the state is often functional and reversible. The evidence supports a real link, not the blanket formulation.
“In men, having too little body fat causes androgen levels to decrease.”
The evidence does not support the general claim that low body fat in men lowers androgens. High-quality studies more consistently show the opposite pattern: higher body fat is associated with lower testosterone, and reducing excess fat often improves it. A possible exception may exist in extreme leanness with severe energy deficit, but that is narrower and less well supported than the claim states.
“Being underweight in women causes excess androgen levels (hyperandrogenism).”
The evidence does not support underweight status as a cause of hyperandrogenism in women. Authoritative endocrine sources instead link underweight states such as functional hypothalamic amenorrhea and anorexia nervosa to low or normal androgen levels, while excess androgens are more commonly driven by PCOS, adrenal disorders, obesity, and insulin resistance. Rare lean-PCOS or atypical cases do not make underweight itself the cause.
“In men, having an excessive amount of body fat causes estrogen levels to become abnormally high.”
Excess body fat in men commonly raises estrogen production through increased aromatase activity, and many studies find higher estradiol or related estrogens in obese men. However, the effect is not universal, and serum estradiol is not always clearly or clinically abnormal in every study or every man. The claim is directionally accurate but stronger than the evidence warrants.
“Obesity in women causes estrogen deficiency.”
The evidence does not support the broad claim as stated. In some premenopausal contexts, obesity is associated with lower estradiol or altered hormone signaling, but after menopause obesity commonly raises estrogen levels because adipose tissue produces estrogen. That means the relationship is bidirectional and depends heavily on menopausal status, so describing obesity in women generally as causing estrogen deficiency is materially misleading.
“Women with insufficient body fat have reduced estrogen levels.”
The evidence strongly supports a real physiological link. Very low body fat is associated with lower estrogen because adipose tissue helps produce estrogen and because low fat often accompanies low energy availability, which can suppress ovarian hormone production. The main caveat is that there is no single body-fat percentage that defines "insufficient" for every woman.
“Being underweight in males causes excess estrogen levels.”
The evidence does not support underweight status as a cause of excess estrogen in males. Medical literature consistently links higher body fat—not low body weight—to higher estradiol because adipose tissue increases aromatization. In men, being underweight is more often associated with lower estrogen levels or broader hormonal suppression, not estrogen excess.
“Wasp stings can have a beneficial effect on osteoarthritis in a specific joint.”
Available evidence does not support the claim as stated. Research on wasp venom is limited to preclinical studies in inflammatory or rheumatoid arthritis models, not human osteoarthritis in a specific joint. The osteoarthritis evidence in the cited literature concerns bee venom—especially knee osteoarthritis—not wasp stings, so the claim overextends limited and mismatched findings.
“Profuse sweating with no apparent cause followed by a spasm-like sensation at the lower end of the esophagus is a warning sign of an impending myocardial infarction (heart attack).”
The evidence does not support this symptom pair as a recognized warning sign of an impending heart attack. Unexplained sweating can occur with myocardial infarction and should not be ignored, but a spasm-like sensation low in the esophagus is more commonly treated as an esophageal mimic or alternative diagnosis, not a cardiac prodrome. The claimed sequence is therefore materially misleading.
“Ex vivo CRISPR-based therapies for sickle cell disease typically require myeloablative conditioning with busulfan before reinfusion of edited hematopoietic stem cells.”
Current evidence shows busulfan-based myeloablation is the standard preparative step before reinfusion in ex vivo CRISPR sickle cell therapies. FDA labeling for Casgevy and published trial reports describe busulfan conditioning, and broader reviews say busulfan remains the usual regimen across these autologous ex vivo approaches. Alternative conditioning strategies exist in research, but they are not yet typical practice.
“Hydroxyurea treatment for sickle cell disease increases fetal hemoglobin production and reduces red blood cell sickling.”
The claim matches the established medical evidence. Hydroxyurea is a standard disease-modifying therapy for sickle cell disease because it raises fetal hemoglobin, which in turn suppresses hemoglobin S polymerization and reduces red blood cell sickling. Individual response varies, but that does not materially change the core conclusion.